Mocetinostat is under clinical development by Mirati Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mocetinostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mocetinostat overview

Mocetinostat is under development for the treatment of non-small cell lung cancer (NSCLC), relapsed and refractory follicular lymphoma and relapsed and refractory Hodgkin lymphoma. It is administered through the oral route. It acts by targeting HDAC (histone deacetylase) I and IV.

It was also under development for the treatment of refractory and recurrent rhabdomyosarcoma, pancreatic cancer, refractory chronic lymphocytic leukaemia (CLL), acute myelocytic leukaemia (AML), Burkitt's lymphoma, non-Hodgkin lymphoma, bladder cancer and myelodysplastic syndrome, metastatic leiomyosarcoma relapsed and refractory diffuse large B-cell lymphoma and urothelial carcinoma.

Mirati Therapeutics overview

Mirati Therapeutics is a clinical-stage oncology company that carries out the research and development of novel therapeutics to address the genetic and immunological promoters of cancer. The company product pipeline includes Adagrasib (MRTX849), an oral small molecule inhibitor of KRASG12C and MRTX1133, a potent small molecule inhibitor of the KRASG12D for the treatment of colorectal and pancreatic cancer. Mirati Therapeutics also offers MRTX1133 – pancreatic cancer and Sitravatinib – Tumor, MRTX1719 -methylthioadenosine phosphorylase (MTAP) deleted cancers and MRTX0902-solid Tumors. The company has partnered with Zai Lab, Beigene, Sanofi, Boehringer, Novartis and Bristol Myers Squibb, among others. It operates in Canada, Netherlands and the US. Mirati Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of Mocetinostat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.